Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

NCT07094048 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma Refractory
Relapsed Multiple Myeloma

Interventions

DRUG: Target trough IgG level of 8-10 g/L
DRUG: Target trough IgG level 4-6 g/L
DRUG: No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L

Sponsor

CHU de Quebec-Universite Laval